Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

857
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
857
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

849
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
849

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of miR-181c-5p Rescues Diabetes-Impaired Angiogenesis in Ischemia and Wound Healing.

Diabetes·2026
Same author

Plasma fatty acid profiles and coronary artery disease burden assessed by coronary CT angiography: an observational study.

Scientific reports·2026
Same author

Apolipoprotein C3 Promotes Angiogenesis in an Inflammatory Mouse Model of Peripheral Artery Disease.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Comorbidities and Symptom Status in Moderate and Severe Aortic Stenosis: A Multicenter Clinical Cohort Study.

JACC. Advances·2024
Same author

Early outcomes following integration of computed tomography (CT) coronary angiography service in an established cardiology practice in disease management.

Journal of cardiovascular computed tomography·2023
Same author

Long-Term Outcomes of Contemporary Percutaneous Coronary Intervention with the Xience Drug-Eluting Stent: Results from a Multicentre Australian Registry.

Journal of clinical medicine·2023

Related Experiment Video

Updated: Apr 3, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

540

Acute high-density lipoprotein therapies.

MyNgan Duong1, Belinda A Di Bartolo, Stephen J Nicholls

  • 1aSouth Australian Health and Medical Research InstitutebDepartment of Medicine, University of Adelaide, Adelaide, South Australia, Australia.

Current Opinion in Lipidology
|September 19, 2015
PubMed
Summary

Strategies targeting high-density lipoprotein (HDL) functionality, not just cholesterol levels, show promise for reducing cardiovascular risk. Infusing HDL may acutely improve atherosclerosis in acute coronary syndrome patients.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Related Experiment Videos

Last Updated: Apr 3, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

540
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • High-density lipoprotein (HDL) possesses atheroprotective properties, making it a target for cardiovascular risk reduction.
  • Recent clinical trials of HDL cholesterol-raising agents have yielded disappointing results, shifting focus to HDL functionality.
  • Impaired HDL function is observed in acute coronary syndromes (ACSs), highlighting the importance of HDL quality over quantity.

Purpose of the Study:

  • To review strategies targeting the atheroprotective properties of HDL.
  • To evaluate the potential impact of acutely promoting HDL functionality for cardiovascular risk reduction.

Main Methods:

  • Review of population and animal studies on HDL and atherosclerotic plaque.
  • Analysis of recent clinical trial outcomes for HDL cholesterol-raising agents.
  • Examination of evidence regarding HDL function in acute coronary syndromes.
  • Assessment of studies investigating HDL infusion in patients with acute ischemic events.

Main Results:

  • Population and animal studies support HDL's protective role against atherosclerotic plaque.
  • Clinical trials of HDL-raising agents have not successfully reduced cardiovascular risk.
  • Evidence indicates impaired HDL function in ACS patients.
  • HDL infusion in patients with recent acute ischemic events demonstrated rapid regression of coronary atherosclerosis.

Conclusions:

  • Infusing HDL shows favorable effects on coronary atherosclerosis in ACS patients.
  • Acutely promoting HDL functionality via infusion presents a potentially beneficial therapeutic strategy for ACS.
  • Further large-scale clinical outcome trials are necessary to fully establish the efficacy of HDL infusion therapy.